MX2024005342A - Análogos de auristatina novedosos e inmunoconjugados de estos. - Google Patents
Análogos de auristatina novedosos e inmunoconjugados de estos.Info
- Publication number
- MX2024005342A MX2024005342A MX2024005342A MX2024005342A MX2024005342A MX 2024005342 A MX2024005342 A MX 2024005342A MX 2024005342 A MX2024005342 A MX 2024005342A MX 2024005342 A MX2024005342 A MX 2024005342A MX 2024005342 A MX2024005342 A MX 2024005342A
- Authority
- MX
- Mexico
- Prior art keywords
- immunoconjugates
- novel auristatin
- novel
- auristatin analogues
- analogues
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163275177P | 2021-11-03 | 2021-11-03 | |
| US202163295476P | 2021-12-30 | 2021-12-30 | |
| PCT/US2022/048735 WO2023081230A1 (en) | 2021-11-03 | 2022-11-02 | Novel auristatin analogs and immunoconjugates thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024005342A true MX2024005342A (es) | 2024-09-27 |
Family
ID=86241915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024005342A MX2024005342A (es) | 2021-11-03 | 2022-11-02 | Análogos de auristatina novedosos e inmunoconjugados de estos. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4426714A4 (https=) |
| JP (1) | JP2024540402A (https=) |
| KR (1) | KR20240110584A (https=) |
| AU (1) | AU2022380491A1 (https=) |
| CA (1) | CA3236944A1 (https=) |
| IL (1) | IL312533A (https=) |
| MX (1) | MX2024005342A (https=) |
| TW (1) | TW202334176A (https=) |
| WO (1) | WO2023081230A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025067221A1 (zh) * | 2023-09-26 | 2025-04-03 | 上海齐鲁制药研究中心有限公司 | 奥瑞他汀衍生物及其抗体药物偶联物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2478912B1 (en) * | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| US20130190248A1 (en) * | 2011-07-26 | 2013-07-25 | Agensys, Inc. | Substituted peptide analogs |
| US20130280282A1 (en) * | 2012-04-24 | 2013-10-24 | Daiichi Sankyo Co., Ltd. | Dr5 ligand drug conjugates |
| WO2015017552A1 (en) * | 2013-08-01 | 2015-02-05 | Agensys, Inc. | Antibody drug conjugates (adc) that bind to cd37 proteins |
| CA3205824A1 (en) * | 2014-10-09 | 2016-04-14 | Genzyme Corporation | Glycoengineered antibody drug conjugates |
| US20170014524A1 (en) * | 2015-07-15 | 2017-01-19 | The California Institute For Biomedical Research | Auristatin-antibody conjugates and uses thereof |
-
2022
- 2022-11-02 MX MX2024005342A patent/MX2024005342A/es unknown
- 2022-11-02 JP JP2024527084A patent/JP2024540402A/ja active Pending
- 2022-11-02 IL IL312533A patent/IL312533A/en unknown
- 2022-11-02 WO PCT/US2022/048735 patent/WO2023081230A1/en not_active Ceased
- 2022-11-02 KR KR1020247017701A patent/KR20240110584A/ko active Pending
- 2022-11-02 AU AU2022380491A patent/AU2022380491A1/en active Pending
- 2022-11-02 CA CA3236944A patent/CA3236944A1/en active Pending
- 2022-11-02 EP EP22890732.5A patent/EP4426714A4/en active Pending
- 2022-11-03 TW TW111142076A patent/TW202334176A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3236944A1 (en) | 2023-05-11 |
| EP4426714A1 (en) | 2024-09-11 |
| AU2022380491A1 (en) | 2024-05-30 |
| TW202334176A (zh) | 2023-09-01 |
| IL312533A (en) | 2024-07-01 |
| KR20240110584A (ko) | 2024-07-15 |
| WO2023081230A1 (en) | 2023-05-11 |
| EP4426714A4 (en) | 2025-10-08 |
| JP2024540402A (ja) | 2024-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022006700A (es) | Compuestos poliheterociclicos como inhibidores de mettl3. | |
| UA130338C2 (uk) | Кон'югат ліганд-лікарський засіб аналога ексатекану, спосіб його отримання та його застосування | |
| ECSP034428A (es) | Ciclopentanoindoles, composiciones conteniendo tales compuestos y su uso | |
| CO2022019316A2 (es) | Inhibidores alostéricos de egfr y métodos de uso de estos | |
| MX2022002740A (es) | Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes. | |
| PE20221417A1 (es) | Degradadores bifuncionales de brd9 y sus metodos de uso | |
| CL2021002503A1 (es) | Anticuerpos contra triptasa, composiciones de estos y usos de estos. (divisional de solicitud 201902251) | |
| MX2022009596A (es) | Anticuerpos anti-ror1 y composiciones. | |
| PE20200494A1 (es) | Polinucleotidos de aadc para el tratamiento de la enfermedad de parkinson | |
| CO2021004789A2 (es) | Piridazinonas y sus métodos de uso | |
| AR123685A1 (es) | Antagonistas del mrgx2 | |
| PA8583101A1 (es) | Nuevos compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf) | |
| JOP20210164A1 (ar) | طرق وتركيبات علاج السرطان | |
| MX389724B (es) | Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo | |
| DOP2018000238A (es) | Inhibidores del potenciador del homólogo zeste 2 | |
| MX2023009874A (es) | Anticuerpos anti-psma y estructuras car-t. | |
| MX2020011826A (es) | Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas. | |
| CL2025002872A1 (es) | Anticuerpos anti-cd19 y estructuras car-t | |
| CR10062A (es) | Composiciones y metodos de tratamiento para trastornos del sistema nervioso central | |
| CO2022006466A2 (es) | Inhibidores de egfr alostéricos y métodos de uso de los mismos | |
| MX2020012281A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
| MX2024005342A (es) | Análogos de auristatina novedosos e inmunoconjugados de estos. | |
| DOP2025000220A (es) | Compuestos bifuncionales capaces de degradar receptores de andrógenos | |
| PA8567701A1 (es) | Agonistas del receptor b3-adrenergico | |
| CO2025002334A2 (es) | Derivados arilos tricíclicos, y composiciones y métodos de los mismos |